Holen Sie sich die Stockscreener-App
1.02
3.03%
0.03
Handel nachbörslich:
1.04
0.02
+1.96%
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
What is HC Wainwright's Forecast for CLSD FY2024 Earnings? - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat
Clearside Biomedical's (CLSD) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.com - MarketBeat
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy - MSN
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Needham & Company LLC Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright - MarketBeat
Clearside Biomedical Announces Slight Revenue Increase in Third Quarter, Advances Wet AMD Treatment in Clinical Trial - Vision Monday
Earnings call: Clearside Biomedical reports progress in AMD treatment - Investing.com
Earnings call: Clearside Biomedical reports progress in AMD treatment By Investing.com - Investing.com Australia
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates - MSN
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2024 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD) - MarketBeat
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights - GuruFocus.com
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Clearside Biomedical Reports Positive Q3 2024 Results - TipRanks
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings: Revenue Surges - GuruFocus.com
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Biomedical earnings beat by $0.02, revenue topped estimates - Investing.com UK
Clearside Biomedical Hits Phase 2b Trial Success, Advances AMD Treatment to Phase 3 | CLSD Stock News - StockTitan
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... By GuruFocus - Investing.com Canada
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For - GuruFocus.com
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years - Yahoo Finance
Clearside Biomedical (NASDAQ:CLSD) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Clearside inks deal to expand eye treatment in China - Investing.com
Clearside inks deal to expand eye treatment in China By Investing.com - Investing.com UK
Clearside Biomedical Partner Arctic Vision Executes - GlobeNewswire
Clearside's Eye Treatment Platform Gains Momentum with Major Santen Partnership in China | CLSD Stock News - StockTitan
Rosalind Advisors Inc. Lowers Stock Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - MarketBeat
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - GlobeNewswire
Clearside Biomedical CEO to Present at Stifel Healthcare ConferenceKey Updates Expected | CLSD Stock News - StockTitan
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - Vision Monday
Clearside Biomedical (CLSD) Scheduled to Post Earnings on Tuesday - MarketBeat
Clearside Biomedical names new board chair By Investing.com - Investing.com Canada
Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Purchases $36,500.00 in Stock - MarketBeat
Clearside Biomedical chief medical officer buys $36,500 in stock - Investing.com
Clearside Biomedical chief medical officer buys $36,500 in stock By Investing.com - Investing.com Australia
Clearside Biomedical names new board chair - Investing.com
Clearside Biomedical to Report Third Quarter 2024 Financial - GlobeNewswire
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - The Manila Times
Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration - 2 Minute Medicine
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.17 - MarketBeat
Short Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Rises By 646.6% - MarketBeat
Clearside Biomedical advances CLS-AX into Phase 3 trials By Investing.com - Investing.com Nigeria
Clearside Biomedical Inc Still Hasn’t Convinced Analysts? - Stocks Register
Clearside Biomedical advances CLS-AX into Phase 3 trials - Investing.com
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - ForexTV.com
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and - GlobeNewswire
Clearside Biomedical (NASDAQ:CLSD) Stock Rating Upgraded by StockNews.com - Defense World
Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Hold at StockNews.com - MarketBeat
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):